ESPR
Esperion Therapeutics Stock Analysis
AI Rating
- Quality0/10
- Growth↑ 8/10
- Value↓ 4/10
ESPR Growth
- Revenue Y/Y↑ 21.31%
- EPS Y/Y↑ 60.71%
- FCF Y/Y↑ 45.38%
ESPR Profitability
- Gross margin ↑ 67.90%
- EPS margin↓ -5.60%
- ROIC 5Y↓ -12.88%
ESPR Risk
- Debt / Equity↑ 999.0
- Debt / FCF↑ 29.0
- Interest coverage↓ 0.8
Esperion Therapeutics stock volatility is in-line with the overall market. We give it a Poor risk rating.